SCHEMBL22980912

SCHEMBL22980912

COc1cccc(C#Cc2cc(F)c(NS(=O)(=O)c3cc(C)cc(F)c3C)c(F)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.54
KMT2A Q03164 4/20 0.54
GAA P10253 1/20 0.54
MAPK1 P28482 1/20 0.54
ALDH1A1 P00352 2/20 0.49
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA9 Q16790 2/20 0.45
FFAR4 Q5NUL3 1/20 0.44
MAPT P10636 1/20 0.44
LMNA P02545 4/20 0.41
MEN1 O00255 3/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
GRM5 P41594 2/20 0.40
HPGD P15428 2/20 0.39
THRB P10828 1/20 0.39
ALOX12 P18054 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29666141 1.00 SMN1; SMN2 (0.54) SMN1; SMN2KMT2AGAAMAPK1ALDH1A1
SCHEMBL23010499 0.87 KMT2A (0.42) SMN1; SMN2KMT2AGAAMAPK1ALDH1A1
SCHEMBL29666220 0.87 KMT2A (0.42) SMN1; SMN2KMT2AGAAMAPK1ALDH1A1
SCHEMBL29666217 0.86 CA12 (0.43) SMN1; SMN2KMT2AGAAMAPK1CA12
SCHEMBL23010524 0.86 CA12 (0.43) SMN1; SMN2KMT2AGAAMAPK1CA12
SCHEMBL22980412 0.85 CA12 (0.41) SMN1; SMN2KMT2AGAAMAPK1ALDH1A1
SCHEMBL29434896 0.85 CA12 (0.41) SMN1; SMN2KMT2AGAAMAPK1ALDH1A1
SCHEMBL22980484 0.85 SMN1; SMN2 (0.49) SMN1; SMN2KMT2AGAAMAPK1ALDH1A1
SCHEMBL29434828 0.85 SMN1; SMN2 (0.49) SMN1; SMN2KMT2AGAAMAPK1ALDH1A1
SCHEMBL22981714 0.85 FFAR4 (0.39) SMN1; SMN2KMT2AGAAMAPK1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12065399-B2 Arylsulfonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2024-08-20 US claimed
EP-4013495-B1 ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS HOFFMANN LA ROCHE (CH) 2023-09-27 EP claimed
EP-4013495-A1 ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS F. Hoffmann-La Roche AG (CH) 2022-06-22 EP claimed
US-20220169599-A1 ARYLSULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2022-06-02 US claimed
CN-114174266-A Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators 豪夫迈·罗氏有限公司 2022-03-11 CN claimed
WO-2021028512-A1 ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2021-02-18 WO claimed
US-12065399-B2 Arylsulfonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2024-08-20 US disclosed
EP-4013495-B1 ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS HOFFMANN LA ROCHE (CH) 2023-09-27 EP disclosed
EP-4013495-A1 ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS F. Hoffmann-La Roche AG (CH) 2022-06-22 EP disclosed
US-20220169599-A1 ARYLSULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2022-06-02 US disclosed
US-20220169599-A1 ARYLSULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2022-06-02 US disclosed
CN-114174266-A Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators 豪夫迈·罗氏有限公司 2022-03-11 CN disclosed
WO-2021028512-A1 ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169599-A1 ARYLSULFONAMIDE DERIVATIVES ARSA, SULT1E1, STS SMN1; SMN2 1681/4885KMT2A 837/4885GAA 1211/4885
US-12065399-B2 Arylsulfonamide derivatives ARSA, SULT1E1, STS SMN1; SMN2 1681/4885KMT2A 837/4885GAA 1211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.